S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Hot Potato: Lamb Weston Stock Confirms a Top 
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Hot Potato: Lamb Weston Stock Confirms a Top 
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Hot Potato: Lamb Weston Stock Confirms a Top 
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Hot Potato: Lamb Weston Stock Confirms a Top 
NYSE:TARO

Taro Pharmaceutical Industries - TARO Stock Forecast, Price & News

$31.36
+0.12 (+0.38%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$30.87
$31.51
50-Day Range
$28.74
$36.53
52-Week Range
$28.46
$65.21
Volume
6,441 shs
Average Volume
14,417 shs
Market Capitalization
$1.18 billion
P/E Ratio
12.96
Dividend Yield
N/A
Price Target
$54.00

Taro Pharmaceutical Industries MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
72.2% Upside
$54.00 Price Target
Short Interest
Healthy
0.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

423rd out of 1,072 stocks

Pharmaceutical Preparations Industry

188th out of 534 stocks

TARO stock logo

About Taro Pharmaceutical Industries (NYSE:TARO) Stock

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.

Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TARO Stock News Headlines

See More Headlines
Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TARO Company Calendar

Last Earnings
7/27/2022
Today
10/06/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
1,455
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$54.00
High Stock Price Forecast
$54.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
+72.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$58.27 million
Pretax Margin
19.27%

Debt

Sales & Book Value

Annual Sales
$561.35 million
Cash Flow
$4.07 per share
Book Value
$45.54 per share

Miscellaneous

Free Float
32,398,000
Market Cap
$1.18 billion
Optionable
Optionable
Beta
0.67

Key Executives

  • Mr. Uday V. Baldota (Age 52)
    CEO & Director
  • Mr. William J. Coote (Age 67)
    VP, CFO & Chief Accounting Officer
  • Mr. Itamar Karsenti (Age 50)
    VP & Head of Operations
  • Mr. Avi Avramoff (Age 57)
    VP and Head of R&D
  • Mr. Itzik Baruch (Age 59)
    VP of Technical Services
  • Dr. Roman Kaplan (Age 75)
    VP of Scientific and Technical Compliance Mang.
  • Mr. Erik Zwicker J.D. (Age 42)
    VP, Gen. Counsel & Sec.
  • Mr. Ara Aprahamian (Age 54)
    VP of Sales & Marketing
    Comp: $616.14k
  • Ms. Michele Visosky (Age 56)
    VP & Head of Human Resource
  • Mr. Jayesh Shah (Age 66)
    Head of Procurement













TARO Stock - Frequently Asked Questions

Should I buy or sell Taro Pharmaceutical Industries stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TARO shares.
View TARO analyst ratings
or view top-rated stocks.

What is Taro Pharmaceutical Industries' stock price forecast for 2022?

1 analysts have issued 12 month target prices for Taro Pharmaceutical Industries' shares. Their TARO share price forecasts range from $54.00 to $54.00. On average, they predict the company's stock price to reach $54.00 in the next year. This suggests a possible upside of 72.2% from the stock's current price.
View analysts price targets for TARO
or view top-rated stocks among Wall Street analysts.

How have TARO shares performed in 2022?

Taro Pharmaceutical Industries' stock was trading at $50.11 at the start of the year. Since then, TARO shares have decreased by 37.4% and is now trading at $31.36.
View the best growth stocks for 2022 here
.

When is Taro Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our TARO earnings forecast
.

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its earnings results on Wednesday, July, 27th. The company reported $0.37 EPS for the quarter, missing analysts' consensus estimates of $0.85 by $0.48. The company earned $156.67 million during the quarter, compared to the consensus estimate of $149.90 million. Taro Pharmaceutical Industries had a trailing twelve-month return on equity of 5.45% and a net margin of 15.96%.

What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO?

11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $31.36.

How much money does Taro Pharmaceutical Industries make?

Taro Pharmaceutical Industries (NYSE:TARO) has a market capitalization of $1.18 billion and generates $561.35 million in revenue each year. The company earns $58.27 million in net income (profit) each year or $2.42 on an earnings per share basis.

How many employees does Taro Pharmaceutical Industries have?

The company employs 1,455 workers across the globe.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The official website for the company is www.taro.com. The company can be reached via phone at (724) 847-5700, via email at investorrelations@taro.com, or via fax at 914-345-6169.

This page (NYSE:TARO) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.